TP53 and neoplasm: In addition, CHK1 inhibitors may be effective, as TP53/RB1 loss leads to compensatory upregulation of the ATR/CHK1 pathway in preclinical studies, which tumor cells depend on to enforce the G2/M checkpoint for DNA damage repair [29].